In addition, NK cells are capable to obtain the tyrosine kinase receptor TYRO3 from leukemia cells in vitro and in vivo, displaying higher levels of activation markers, enhanced cytotoxicity and interferon-γ secretion (49), thus providing opposing evidence that tumor receptor trogocytosis on NK cells could also translate into gain of anti-tumor activity and effector function (56). The gene discussed is TYRO3; the disease is neoplasm.